ArticleDer Pathologe2016
[The WHO/ISUP grading system for renal carcinoma].
Article in Der Pathologe, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.Journal for immunotherapy of cancer · 2026Guideline
- Accuracy of CT texture analysis for differentiating low-grade and high-grade renal cell carcinoma: systematic review and meta-analysis.BMJ open · 2021Pooled it
- Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2018Pooled it
- Tumor Heterogeneity of RCCs Assessed by mpMRI with Direct Radiological-Histopathological Correlation.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Exploration of prognostic prediction models for renal cell carcinoma using diffusion relaxation correlation spectroscopic imaging.BMC medical imaging · 2026Article
- MorphoITH: a framework for deconvolving intra-tumor heterogeneity using tissue morphology.Genome medicine · 2025Article
- Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers: an update after ISUP/WHO 2022 classification.The journal of pathology. Clinical research · 2025Article
- Chromophobe renal cell carcinoma - a rare kidney cancer with limited therapy options: a narrative review.BMC urology · 2025Review
- Radiomics-Based Classification of Clear Cell Renal Cell Carcinoma ISUP Grade: A Machine Learning Approach with SHAP-Enhanced Explainability.Diagnostics (Basel, Switzerland) · 2025Article
- Molecular dynamics reveal potential effects of novel VHL variants on VHL-Elongin C binding in ccRCC patients from Eastern India.Scientific reports · 2025Article
- Using three-dimensional virtual imaging of renal masses to improve prediction of robotic-assisted partial nephrectomy Tetrafecta with SPARE score.World journal of urology · 2024Article
- Predictive nomogram for ischemic stroke risk in clear cell renal cell carcinoma patients.Scientific reports · 2024Article
- The value of radiomics based on 2-[18 F]FDG PET/CT in predicting WHO/ISUP grade of clear cell renal cell carcinoma.EJNMMI research · 2024Article
- Bioinformatic Approaches for the Identification of Novel Tumor Suppressor Genes and Cancer Pathways in Renal Clear Cell Carcinoma.Iranian journal of biotechnology · 2024Article
- Tumor Necrosis Factor Receptor-2 Signals Clear-Cell Renal Carcinoma Proliferation via Phosphorylated 4E Binding Protein-1 and Mitochondrial Gene Translation.The American journal of pathology · 2024Article
- Investigation of clear cell renal cell carcinoma grades using diffusion-relaxation correlation spectroscopic imaging with optimized spatial-spectrum analysis.The British journal of radiology · 2024Article
- Non-annotated renal histopathological image analysis with deep ensemble learning.Quantitative imaging in medicine and surgery · 2023Article
- SLUG and SNAIL as Potential Immunohistochemical Biomarkers for Renal Cancer Staging and Survival.International journal of molecular sciences · 2023Article
- Proteomic analysis identifies HMGA2 as a novel biomarker of overall survival in papillary renal cell carcinoma.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histological tumor grading is an accepted prognostic parameter of renal cell carcinoma (RCC). In 2012, the International Society of Urologic Pathologists (ISUP) proposed a novel grading system for RCC, mainly based on the evaluation of nucleoli: grade 1 tumors have nucleoli that are inconspicuous and basophilic at ×400 magnification; grade 2 tumors have nucleoli that are clearly visible at ×400 magnification and eosinophilic; grade 3 tumors have clearly visible nucleoli at ×100 magnification; and grade 4 tumors have extreme pleomorphism or rhabdoid and/or sarcomatoid morphology. This grading system was validated for clear cell renal cell carcinoma and papillary renal cell carcinoma. At the same time, the ISUP proposed not grading chromophobe renal cell carcinomas according to this system. At a consensus conference in Zurich the World Health Organization (WHO) recommended the ISUP grading system; thus, the WHO/ISUP grading system is now going to be implemented internationally. The ISUP/WHO grading system has not been validated as a prognostic parameter for other tumor subtypes, but can be used for descriptive purposes.
Indexed as
Identifiers
27271258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.